I’ve made mention of the European College of Neuropharmacology that was meeting in Paris last week There’s a video presentation of a panel describing the goings on there now on their website that’s worth watching if you’ve got 30 minutes with nothing to do [Highlights 24th ECNP Congress]. Knowing that you’re unlikely to do that, […]
In the course of looking at some of the writing about the DSM-5, I was sent a recent speech by Dr. Tom Insel, Director of the NIMH [class action in the air…] that began with one of his signature topics: The field of mental health is on the cusp of a revolution, which is set […]
Having been in the trenches for five months, I had passed my prime. For the first three weeks, an officer was of little use in the front line; he did not know his way around, had not learned the rules of health and safety, or grown accustomed to recognizing the degree of danger. Between three […]
This book is to be neither an accusation nor a confession, and least of all an adventure, for death is not an adventure to those who stand face to face with it. It will try simply to tell of a generation of men who, even though they may have escaped its shells, were destroyed by […]
Sometimes, retirement days get filled up and the everyday business of working life returns – a reminder of why one retires in the first place. The last few days have been like that – meetings, weddings, old friends not seen for years. But on the side of my mind, something about that speech of NIMH […]
Neuroscience, Clinical Evidence, and the Future of Psychiatric Classification in DSM-5 by David J. Kupfer, M.D. and Darrel A. Regier, M.D., M.P.H. American Journal of Psychiatry 168:672-674, 2011. In the initial stages of development of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders,we expected that some of the limitations of the […]
Drug development for anxiety disorders: new roles for atypical antipsychotics by Carson WH, Kitagawa H, Nemeroff CB Psychopharmacology Bulletin 2004;38 Suppl 1:38-45. Source: Global Product Development/Aripiprazole, Princeton Aripiprazole Unit, Otsuka America Pharmaceutical, Inc., in Princeton, NJ. Abstract: Anxiety disorders are prevalent and frequently comorbid with depression. Rates of response and remission for anxiety disorders are […]
Is the DSM-V Necessary? NEI Blog by Dr. Stephen Stahl September 06, 2011 We don’t need a new version of the DSM now. I am blogging today from Paris at the ECNP meeting, having attended the Royal Society of Medicine meeting outside of London last week to discuss the future of new drug development in […]
When one sees the size of the settlements in the civil suits against the pharmaceutical industry, the numbers [in the millions] seem impressive. Then if you look at the corporate profits [in billions], those settlements don’t look quite so large anymore. So we make the same old "cost of doing business" comment and wish for […]
BUILDING A NATIONAL MENTAL HEALTH SYSTEM: A 21st Century Engineering Challenge Croaky: The Crikey Health Blog by Jennifer Doggett September 5, 2011 Professor Pat McGorry, Executive Director, Orygen Youth Health Research Centre, will appear today from Europe via videolink to provide evidence to the Senate Inquiry into the Budget mental health initiatives. Here is a […]